Empliciti 400mg(elotuzumab)

Reference priceRUB ₽57,750.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.

Brand	Empliciti
Manufacturer	Bristol-Myers Squibb/AbbVie
Prescription required	Yes

Description

Empliciti 400mg(elotuzumab) is a medicine catalog record in the MediPriceHub database. Active ingredient: elotuzumab. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Bristol-Myers Squibb/AbbVie. Therapeutic category: Medicine Library > Oncology Medicines > Myeloma (myelofibrosis) drugs. Pack information: 400. Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.

Benefits

• EMPLICITI is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies. • EMPLICITI is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

How to Use

Use elotuzumab under the supervision of a qualified healthcare professional. Use it only according to the approved label and the instructions of a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.

Specification

Active ingredient: elotuzumab. Pack size: 400. Pack unit: bottle. Manufacturer: Bristol-Myers Squibb/AbbVie. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Myeloma (myelofibrosis) drugs. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.

Side Effects

The available source record does not provide a clean, product-specific adverse-reaction list. Potential risks depend on the active ingredient, dose, route, treatment duration, and patient condition. Check the approved local prescribing information for the complete adverse-reaction profile, warnings, contraindications, and monitoring requirements. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, serious bleeding, or rapidly worsening symptoms.

Эта информация носит справочный характер. Перед применением лекарства проконсультируйтесь с медицинским специалистом.